Yahoo Finance InspireMD Reports Second Quarter 2022 Financial Results and Provides Business Update
- Generated 47.8% growth in CGuard™ revenue year-over-year -
- Delivered several presentations at LINC 2022 featuring CGuard™ EPS, including a successful live case transmission -
- Announced that endovascular pioneer Dr. Juan Parodi has agreed to act as strategic advisor to the company -
--
Management to Host Investor Conference Call Today, August 9th, at 8:30am ET
--
TEL AVIV, Israel, Aug. 09, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for treatment of carotid artery disease and prevention of stroke today announced financial and operating results for the second quarter ended June 30, 2022.
Second Quarter 2022 and Recent Highlights:
CGuard revenues for the second quarter 2022 were $1,505,000, a 47.8% increase over the same period in 2021, on 2,602 stent systems sold, as compared to 1,623 stents sold in the same period in 2021.
Continued enrollment in the C-Guardian Investigational Device Exemption (IDE) Clinical Trial. The Company completed its first European enrollment in April, led by co-principal investigator Professor Piotr Musialek, at John Paul II Hospital, in Krakow, Poland. The company currently has 20 trial sites enrolling patients and anticipates adding seven more by the end of the year. The company anticipates completing enrollment in Q1 2023.
Delivered several presentations at LINC 2022 featuring CGuard™ EPS, including a live case transmission on a 62-year-old asymptomatic male with progressive and calcified internal carotid critical stenosis. The procedure was successfully performed with the 10mm x 30mm CGuard™ EPS and produced an excellent angiographic result.
Announced that endovascular pioneer Dr. Juan Parodi has agreed to act as strategic advisor to the company. Dr. Parodi is credited with performing the first endovascular repair procedure in 1990 and the first TCAR procedure in 1994.
Marvin Slosman, CEO of InspireMD, commented: “Our second quarter revenue results again demonstrated our ability to gain share in our key European markets. With 48% growth in revenue in the quarter, respectively, over the same quarterly period last year, we believe we are well on our way to establishing CGuard™ EPS as a ‘new’ standard of care for the management of carotid artery disease and stroke prevention.”
“Regarding our U.S. IDE trial, we now have 22 sites enrolling patients, and plan to bring an additional seven online by the end of the year. Enrollment is accelerating and tracking nicely, and we continue to anticipate having the trial fully enrolled by approximately Q1 of next year.”
“We expect future growth to be driven by continued market share gains, additional geographic expansion, and the introduction of our new stent delivery systems, CGuard Prime and Switchguard. I look forward to continued momentum and I am beyond excited for what the future holds, not only for our company, but for CAD patients and their treating physicians as well,” Mr. Slosman concluded.
Financial Results for the Second Quarter ended June 30, 2022
For the second quarter of 2022, total revenue increased 47.6%, to $1,531,000, from $1,038,000 during the second quarter of 2021. This increase was predominantly driven by a 47.8% increase in sales volume of CGuard EPS, to $1,505,000 in the second quarter of 2022 from $1,019,000 in the same period one year ago. This sales increase was mainly due to growth in existing and new markets as well as US sales related to stents used in the C-Guardian U.S. Food and Drug Administration (FDA) clinical trial.
Gross profit for the second quarter of 2022 increased by $169,000, or 64.4%, to $431,000, compared to a gross profit of $262,000 for the second quarter of 2021. This increase resulted from higher revenue and a reduction in miscellaneous expenses of $55,000, partially offset by a $83,000 reduction in costs of goods sold due to an inventory adjustment that occurred during the three months ended June 30, 2021 which did not occur during the three months ended June 30, 2022. Gross margin (gross profits as a percentage of revenue) increased to 28.1% during the three months ended June 30, 2022 from 25.2% during the three months ended June 30, 2021.
Total operating expenses for the second quarter of 2022, were $5,112,000, an increase of $1,410,000, or 38.1% compared to $3,702,000 for the second quarter of 2021. This increase was primarily due to increases in expenses related to the commencement of the C-Guardians FDA study, resumed activities in tradeshows, travel and share-based compensation.
Net loss for the second quarter of 2022 totaled $4,636,000, or $0.59 per basic and diluted share, compared to a net loss of $3,507,000, or $0.46 per basic and diluted share, for the same period in 2021.
As of June 30, 2022, cash, cash equivalents and short-term bank deposits were $26.5 million compared to $34.0 million as of December 31, 2021.
Financial Results for the Six Months ended June 30, 2022
For the six months ended June 30, 2022, total revenue increased by $670,000, or 32.8%, to $2,714,000, from $2,044,000 during the six months ended June 30, 2021. This increase was predominantly driven by a 34.2% increase in sales volume of CGuard EPS, to $2,666,000 during the six months ended June 30, 2022 from $1,987,000 during the six months ended June 30, 2021. This sales increase was mainly due to growth in existing and new markets and sales in the United States related to stents used in our C-Guardians FDA study which occurred in the six months ended June 30, 2022, but not in the corresponding period in 2021.
Gross profit for the six months ended June 30, 2022 increased by $185,000, or 50.2%, to $553,000, compared to a gross profit of $368,000 for the six months ended June 30, 2021. This increase in gross profit resulted from higher revenue, partially offset by an increase of $38,000 in miscellaneous expenses. Gross margin (gross profits as a percentage of revenue) increased to 20.4% during the six months ended June 30, 2022 from 18% during the six months ended June 30, 2021.
Total operating expenses for the six months ended June 30, 2022, were $9,720,000, an increase of $2,598,000, or 36.5% compared to $7,122,000 for the six months ended June 30, 2021. This increase was primarily due to increases in expenses related to the commencement of the C-Guardians FDA study, share-based compensation and resumed activities in tradeshows and travel.
Net loss for the six months ended June 30, 2022 totaled $9,117,000, or $1.17 per basic and diluted share, compared to a net loss of $6,750,000, or $0.98 per basic and diluted share, for the six months ended June 30, 2021.
Conference Call and Webcast Details
Management will host a conference call at 8:30AM ET today, August 9, to review financial results and provide an update on corporate developments. Following management’s formal remarks, there will be a question-and-answer session.
Tuesday, August 9th at 8:30 a.m. ET | ||
|
|
|
| Domestic: | 855-327-6837 |
| International: | 631-891-4304 |
| Conference ID: | 10019719 |
| Webcast: | |
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes. InspireMD’s common stock is quoted on the Nasdaq under the ticker symbol NSPR.
For more information, please visit www.inspiremd.com.
Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” “scheduled” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, including the changing regulatory environment in Europe and the timing of the renewal of certificate to continue to sell CGuard under the new MDR rule structure, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Investor Contacts:
Craig Shore
Chief Financial Officer
InspireMD, Inc.
888-776-6804
craigs@inspiremd.com
Chuck Padala, Managing Director
LifeSci Advisors
646-627-8390
chuck@lifesciadvisors.com
investor-relations@inspiremd.com
CONSOLIDATED STATEMENTS OF OPERATIONS(1) | ||||||||||||||||||
(U.S. dollars in thousands, except per share data) | ||||||||||||||||||
|
| Three months ended | Six months ended | |||||||||||||||
|
| |||||||||||||||||
| June 30, | June 30, | ||||||||||||||||
|
| 2022 |
| 2021 |
| 2022 |
| 2021 | ||||||||||
|
|
|
|
|
|
|
|
| ||||||||||
|
|
|
|
|
|
|
|
| ||||||||||
Revenues |
| $1,531 |
|
| $1,038 |
|
| $2,714 |
|
| $2,044 |
| ||||||
Cost of revenues |
|
| 1,100 |
|
|
| 776 |
|
|
| 2,161 |
|
|
| 1,676 |
| ||
|
|
|
|
|
|
|
|
| ||||||||||
Gross Profit |
|
| 431 |
|
|
| 262 |
|
|
| 553 |
|
|
| 368 |
| ||
|
|
|
|
|
|
|
|
| ||||||||||
Operating Expenses: |
|
|
|
|
|
|
|
| ||||||||||
Research and development |
|
| 2,056 |
|
|
| 1,290 |
|
|
| 3,736 |
|
|
| 2,129 |
| ||
Selling and marketing |
|
| 986 |
|
|
| 636 |
|
|
| 1,732 |
|
|
| 1,344 |
| ||
General and administrative |
|
| 2,070 |
|
|
| 1,776 |
|
|
| 4,252 |
|
|
| 3,649 |
| ||
|
|
|
|
|
|
|
|
| ||||||||||
Total operating expenses |
|
| 5,112 |
|
|
| 3,702 |
|
|
| 9,720 |
|
|
| 7,122 |
| ||
|
|
|
|
|
|
|
|
| ||||||||||
Loss from operations |
|
| (4,681 | ) |
|
| (3,440 | ) |
|
| (9,167 | ) |
|
| (6,754 | ) | ||
|
|
|
|
|
|
|
|
| ||||||||||
Financial income (expenses) |
|
| 45 |
|
|
| (67 | ) |
|
| 50 |
|
|
| 4 |
| ||
|
|
|
|
|
|
|
|
| ||||||||||
Net Loss |
| $(4,636 | ) |
| $(3,507 | ) |
| $(9,117 | ) |
| $(6,750 | ) | ||||||
|
|
|
|
|
|
|
|
| ||||||||||
Net loss per share – basic and diluted |
| $(0.59 | ) |
| $(0.46 | ) |
| $(1.17 | ) |
| $(0.98 | ) | ||||||
|
|
|
|
|
|
|
|
| ||||||||||
Weighted average number of shares of common stock used in computing net loss per share – basic and diluted |
|
| 7,807,795 |
|
|
| 7,704,707 |
|
|
| 7,806,030 |
|
|
| 6,918,090 |
| ||
CONSOLIDATED BALANCE SHEETS(2) | |||||||
(U.S. dollars in thousands) | |||||||
ASSETS | June 30, |
| December 31, | ||||
2022 |
| 2021 | |||||
|
|
|
| ||||
Current Assets: |
|
|
| ||||
Cash and cash equivalents | $6,393 |
|
| $12,004 |
| ||
Short-term bank deposits |
| 20,078 |
|
|
| 22,036 |
|
Accounts receivable: |
|
|
| ||||
Trade, net |
| 1,183 |
|
|
| 1,224 |
|
Other |
| 171 |
|
|
| 165 |
|
Prepaid expenses |
| 221 |
|
|
| 522 |
|
Inventory |
| 1,454 |
|
|
| 1,143 |
|
|
|
|
| ||||
Total current assets |
| 29,500 |
|
|
| 37,094 |
|
|
|
|
| ||||
|
|
|
| ||||
Non-current assets: |
| ||||||
Property, plant and equipment, net |
| 700 |
|
|
| 632 |
|
Operating lease right of use assets |
| 1,717 |
|
|
| 1,081 |
|
Funds in respect of employee rights upon retirement |
| 849 |
|
|
| 905 |
|
|
|
|
| ||||
Total non-current assets |
| 3,266 |
|
|
| 2,618 |
|
|
|
|
| ||||
Total assets | $32,766 |
|
| $39,712 |
| ||
LIABILITIES AND EQUITY |
| June 30, |
| December 31, | ||||
| 2022 |
| 2021 | |||||
|
|
|
|
| ||||
Current liabilities: |
|
|
|
| ||||
Accounts payable and accruals: |
|
|
|
| ||||
Trade |
| $1,127 |
|
| $893 |
| ||
Other |
|
| 3,585 |
|
|
| 3,454 |
|
|
|
|
|
| ||||
Total current liabilities |
|
| 4,712 |
|
|
| 4,347 |
|
|
|
|
|
| ||||
Long-term liabilities: |
|
|
|
| ||||
Operating lease liabilities |
|
| 1,350 |
|
|
| 781 |
|
Liability for employees rights upon retirement |
|
| 962 |
|
|
| 1,052 |
|
Total long-term liabilities |
|
| 2,312 |
|
|
| 1,833 |
|
|
|
|
|
| ||||
Total liabilities |
| $7,024 |
|
| $6,180 |
| ||
|
|
|
|
| ||||
Equity: |
|
|
|
| ||||
Common stock, par value $0.0001 per share; 150,000,000 shares authorized at June 30, 2022 and December 31, 2021; 8,323,200 and 8,296,256 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively |
|
| 1 |
|
|
| 1 |
|
Preferred C shares, par value $0.0001 per share; |
| * |
|
| * |
| ||
Additional paid-in capital |
|
| 217,952 |
|
|
| 216,625 |
|
Accumulated deficit |
|
| (192,211 | ) |
|
| (183,094 | ) |
|
|
|
|
| ||||
Total equity |
|
| 25,742 |
|
|
| 33,532 |
|
|
|
|
|
| ||||
Total liabilities and equity |
| $32,766 |
|
| $39,712 |
| ||
|
|
|
|
| ||||
(1) All 2022 financial information is derived from the Company’s 2022 unaudited financial statements, as disclosed in the Company’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission; all 2021 financial information is derived from the Company’s 2021 unaudited financial statements, as disclosed in the Company’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission.
(2) All June 30, 2022 financial information is derived from the Company’s 2022 unaudited financial statements, as disclosed in the Company’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission. All December 31, 2021 financial information is derived from the Company’s 2021 audited financial statements as disclosed in the Company’s Annual Report on Form 10-K, for the twelve months ended December 31, 2021 filed with the Securities and Exchange Commission.
